TIDMIXI
IXICO plc
02 December 2019
2(nd) December 2019
IXICO plc
("IXICO" or the "Company")
IXICO to Present Abstracts at Upcoming Clinical Trials on
Alzheimer's Disease Congress
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience clinical drug development, today announces
that it is scheduled to attend and present scientific posters at
the 2019 Clinical Trials on Alzheimer's Disease (CTAD) Congress
held from 4(th) -7(th) December 2019 in San Diego, California,
USA.
CTAD Congress 2019
4(th) - 7(th) December 2019, Hilton Bayfront, San Diego, USA
IXICO will present three posters during break-out sessions in
the Indigo Foyer on Thursday, 5(th) December. Details of the
posters are as follows:
"Classifying cognitively healthy subjects from mild cognitive
impaired and Alzheimer's disease patients using Tau-PET: the role
of spatial resolution and PET pre-processing"
Given the connection between Alzheimer's disease and the spatial
bio-distribution of misfolded phosphorylated Tau protein, this
research investigates how the uptake of Tau-PET scans differs in
patients affected with different degrees of cognitive
impairment.
Poster authors:
Richard Joules(1) , Alessandro Palombit(1) , Richard Manber(1) ,
Richard Parker(1) , Robin Wolz(1,2)
Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College
London, UK
"A fully automatic pipeline for estimation of regional brain
volume change using Jacobian Integration"
The poster highlights the methods used for estimating regional
brain volume change in Alzheimer's disease patients, by validating
the fully automatic Jacobian Integration pipeline using LEAP
technology against the commonly accepted standard Boundary Shift
Integration (BSI) method when estimating volume change in the
lateral ventricles of an Alzheimer's disease cohort.
Poster authors:
Richard Joules(1) , Robin Wolz(1,2) , Richard Parker(1)
Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College
London, UK
"A pipeline for automated diffusion MRI analysis: overview and
application to the study of Alzheimer's disease"
This research introduces and validates a pipeline for the
analysis of diffusion MRI brain scan data that is fully integrated
into IXICO's trial management software, TrialTracker(TM): a
web-based tool for data upload, storage, data analysis and quality
assessment of processed data. The pipeline is applied to a cohort
of older adults with and without Alzheimer's disease.
Poster authors:
Richard Joules(1) , Robin Wolz(1,2) , Richard Parker(1)
Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College
London, UK
Alison Howie, Chief Product Officer of IXICO, commented: "We are
delighted to be presenting three abstracts at this year's CTAD
Congress, demonstrating IXICO's expertise in advancing data
analytics to deliver intelligent insights which are vital in
ensuring the successful progression of clinical trials. IXICO's key
mission is the development of data analytics to speed the
advancement of effective treatments for neurodegenerative diseases,
like Alzheimer's disease, that tragically affect so many patients
worldwide."
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Alison Howie, Chief Product Officer
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manel Mateus
IXICO@optimumcomms.com
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of Artificial
Intelligence (AI) in clinical development, to improve biopharma
R&D productivity through the adoption of breakthrough data
analytics in precision healthcare. Through the deployment of novel
AI algorithms, we analyse and interpret brain scans and digital
biosensor data to enable better trial design, patient selection and
ultimately clinical outcomes across all phases of clinical
evaluation. Our data analytics services are deployed on some of the
most important clinical trials in neuroscience and rare disease,
providing valuable insights to disease progression and patient
safety, enabling our clients to make better informed decisions
earlier in the clinical development pathway.
More information is available on www.IXICO.com
About CTAD Congress 2019
The development of the next generation of Alzheimer's disease
treatments is among the most important health needs worldwide but
presents huge challenges. The goal of the meeting is to bring
together today's worldwide leaders in the treatment of Alzheimer's
disease to discuss new results, candidate therapeutics, and
methodological issues important to the development of the next
generation of Alzheimer's disease treatments.
Clinical trial teams from worldwide centres report on their
efforts to identify new biomarkers of disease as well as more
sensitive clinical assessment tools to identify those at risk from
Alzheimer's disease, to predict progression, and assess the
effectiveness of new treatments.
https://www.ctad-alzheimer.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAMMMZMVLVGLZM
(END) Dow Jones Newswires
December 02, 2019 02:01 ET (07:01 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2023 to Apr 2024